Metabolomics Analysis of Acute Kidney Injury and Delirium After Cardiac Surgery (NCT06508593) | Clinical Trial Compass
CompletedNot Applicable
Metabolomics Analysis of Acute Kidney Injury and Delirium After Cardiac Surgery
China120 participantsStarted 2024-07-20
Plain-language summary
Clinical evidence suggests that renal injury leads to changes in the structure of the cerebral cortex in patients, suggesting the existence of the renal brain axis. Therefore, some scholars have proposed that AKI may be an important cause of secondary injuries such as delirium. Approximately 60% of AKI patients in clinical practice experience delirium.Although the underlying mechanism associated with acute renal injury and delirium is still unclear, it has been recognized that it increases incidence rate and mortality, prolongs hospital stay, and accelerates long-term cognitive decline. The investigators assume that the serum metabolic profiles of patients with delirium and AKI after cardiac surgery, with delirium only, with AKI only, and without delirium or AKI after surgery can be compared separately to explore the mechanisms of complications and the interaction mechanisms between organ damage after extracorporeal circulation cardiac surgery, and to identify metabolic markers specific to complications, identify patients with increased susceptibility, and provide reference for early diagnosis of complications and basis for early intervention.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18 years old and above
✓. Patients undergone elective cardiac surgery
✓. History of serum creatinine test within 7 days before surgery
✓. Provide venous blood samples
✓. Voluntarily participate and sign an informed consent form
Exclusion criteria
✕. Patients treated with chronic peritoneum or hemodialysis, prior kidney transplantation, preoperative serum creatinine level\>4.5mg/dL (400 μ mol/L) or end-stage renal disease (defined as glomerular filtration rate\<15ml · min-1 · 1.73m-2)
✕. Other related diseases that have been previously confirmed to have cognitive impairment, or records of using drugs targeting cognitive impairment during the onset period
✕. Individuals with severe speech, visual, hearing, or mental impairments that affect cognitive scale assessment
✕. Individuals with a history of brain tumors, traumatic brain injury, brain parasitic diseases, and other diseases that may cause cognitive impairment
What they're measuring
1
Small molecule metabolites specific to complications after extracorporeal circulation cardiac surgery